Background. We explored biologics receipt in metastatic colon cancer. Methods. We used Surveillance, Epidemiology, and End Results-Medicare data of 4,545 elderly patients diagnosed with incident metastatic colon cancer from 2003 to 2009, treated with chemotherapy and/or biologics, and followed up through 2010. Results. A total of 2,504 (55%) patients received a biologicscontaining regimen. Treatment with biologics fluctuated between 46% and 63% of first-line regimens and 67% and 73% of second-line regimens. Bevacizumab accounted for 95% of first-line and 68% of second-line biologics use. Cetuximab accounted for 33% of second-line and 48% of third-line use. Panitumumab accounted for 5% of second-line and 27% of third-line use.The adjusted odds of biologics receipt decreased rapidly with age, resulting in a threefold difference between
INTRODUCTION
Patients with metastatic colon cancer disease may be treated with one or more chemotherapy and biologic targeted therapy drugs. The list of approved drugs during our study period includes the chemotherapy drugs fluorouracil (and capecitabine) (5FU), leucovorin (LV), oxaliplatin (OX), and irinotecan (IRI) and the biologic drugs bevacizumab (BEV), cetuximab (CET), and panitumumab (PAN).
BEV is an inhibitor of the vascular endothelial growth factor receptor. It was approved for first-line use in 2004 and for second-line use in 2006 [1, 2] . In comparison, CET and PAN, which work by inhibiting epidermal growth factor receptor (EGFR), were approved in 2004 and 2006, respectively, as single or adjunctive agents in patients who had failed or were intolerant to specific chemotherapies [2] [3] [4] .
In 2006 and 2007, the scientific community became increasingly aware that certain KRAS mutations decreased the treatment response of EGFR inhibitors [5] [6] [7] [8] [9] [10] [11] . As a result, the U.S. KRAS mutations in codon 12 or 13, which occur in 39%-43% of metastatic colon cancer patients [12, 13] .
Colon cancer drugs are typically combined into a treatment regimen. When one regimen becomes ineffective or results in significant toxicities, patients may discontinue treatment or continue with another set of drugs.Thus, patients may receive multiple lines of treatment [14, 15] .
This article examines the use of biologic targeted-therapy drugs among elderly patients with metastatic colon cancer disease. Because elderly patients are often underenrolled in clinical trials [16] , we used historical claims-based data to find the factors associated with biologics receipt outside of the clinical trial setting and document how these drugs are used along the treatment continuum.
MATERIALS AND METHODS

Data
This study used Surveillance, Epidemiology, and End Results (SEER)-Medicare data. The SEER program provides demographic and clinical information for all incident cancer cases in 17 geographic regions in the U.S. Medicare, the primary health care provider for the elderly in the U.S., collects information about covered health care services from time of enrollment until death. The linkage of individuals in the SEER cancer registry data to their Medicare claims is performed by the National Cancer Institute and the Centers for Medicare and Medicaid Services.
Population
The study population consisted of elderly (aged . 
Study Sample
We included only patients who were treated with chemotherapy or biologics during the observation period. Furthermore, only patients with complete Medicare coverage (i.e., with both Medicare parts A and B) were included to minimize bias caused by unobserved claims data.
Patients enrolled in a managed care plan in the year before cancer diagnosis were excluded, because we did not have data about their health care utilization. People diagnosed postmortem with metastatic colon cancer were also excluded.
The remaining 4,545 patients were followed up until December 31, 2010. Subjects were censored from the study upon loss of complete Medicare coverage or upon enrollment in a managed care plan.
Treatment Detection
Receipt of specific chemotherapy or biologic drugs was assessed from claims in the period after cancer diagnosis using Healthcare Common Procedure Coding System (HCPCS) codes and National Drug Code (NDC) codes. All claim types, including Part D claims for outpatient drug coverage, were used to detect chemotherapy and biologic treatment. For the purposes of this study, we did not distinguish between capecitabine and its intravenous equivalent, fluorouracil.
Treatment Classification
The claims-based algorithm of Bikov et al. [17] 
Statistical Analysis
We used univariate descriptive analyses to examine the sociodemographic and clinical characteristics of our cohort. Using descriptive bivariate analyses, we compared prevalence rates of biologics receipt across patient groups defined by age, race/ethnicity, gender, marital status, Medicare state buyin assistance (a proxy indicator for low income), urban living area, Charlson Comorbidity Index (CCI), myocardial infarction, chronic heart failure, cerebrovascular disease, chronic obstructive pulmonary disease, chronic renal failure, peripheral vascular disease, and diabetes mellitus. In addition, the unadjusted rates of biologics use in first-and second-line therapy were stratified by age group. Pearson x 2 and t tests were used to compare frequency distributions of categorical and continuous variables, respectively.
We conducted multivariable logistic analysis to assess the adjusted effect of sociodemographic and clinical factors on receipt of biologic therapy. Our full model included the following independent variables: age, race/ethnicity, gender, marital status, Medicare state buy-in assistance, urban living area, CCI, year ofcancerdiagnosis, and SEER cancer registry. An alternative model included variables for myocardial infarction, chronic heart failure, cerebrovascular disease, chronic obstructive pulmonary disease, chronic renal failure, peripheral vascular disease, and diabetes mellitus in place of CCI. Our sensitivity analysis consisted of running multiple logistic regressions, each with a different subset of the independent variables.
Analyses were performed using SAS 9.3 (SAS Institute, Cary, NC, http://www.sas.com/en_us/home.html), and p , .05 was considered statistically significant.
IRB Protocol
The approved Institutional Review Board protocol number at the University of Maryland, Baltimore, was HP-00049426.
RESULTS
The study sample consisted of 4,545 elderly patients who received one or more lines of treatment after being diagnosed with incident metastatic colon cancer. Overall, 2,504 (55%) study participants were treated with biologics during the observation period. Of these, 2,001 (80%) began cancer treatment with a biologics-containing regimen; the remainder began with a chemotherapy-only regimen and did not start 
Biologics Receipt in First-Line Treatment
With the exception of 73 study participants who received only targeted therapy, almost everyone began cancer treatment with a chemotherapy regimen (Fig. 3A) . The three most common regimens were OX-based (51%), 5FU/LV-based (31%), and IRI-based (14%). As many as 1,928 (43%) patients received both chemotherapy and biologics. BEV, which accounted for virtually all biologics use in first line, was included in 55% of OX-based regimens, 34% of IRI-based regimens, and only 21% of 5FU/LV-based regimens (Table 1) . Meanwhile, CET, which accounted for only 3% of first-line regimens, was prescribed more frequently with IRI (5%) compared with OX (2%).
Biologics Receipt in Second-Line Treatment
Approximately two of five treated patients (1,914 [42%]) eventually discontinued their initial treatment and continued with a new treatment regimen (Fig. 3B) . The remaining 2,631 (58%) patients stopped treatment altogether, of whom 984 died within a month (Fig. 1) .
The transition from first-to second-line treatment was typically characterized by the replacement of one backbone chemotherapy drug with another (Table 1) . Most patients received an IRI-based (66%) or OX-based (25%) second-line regimen (Fig. 3B) . Use of targeted therapy in second line increased by 17 percentage points compared with first line. Overall, 1,173 (61% of those who progressed to second line) received biologics. Table 2 shows the relative utilization of BEV, CET, and PAN as part of the three most common second-line treatments. BEV, which was included in 39% of second-line regimens, continued to be the most frequently prescribed biologic. It was added to 44% of OX-based and 42% of IRI-based treatments. CETwasused in 20% of second-line regimens. This dramatic increase was driven by the popularity of IRI-based regimens, which were four times more likely to include CET compared with OX-based regimens. PAN saw little use (3% of second-line regimens) and was mostly limited to regimens consisting of biologics only, which accounted for 127 (7%) of second-line treatments.
Biologics Receipt in Third-Line Treatment
Only 323 patients (or 7% of our sample) eventually progressed to third-line treatment. Of these, 221 (68%) were treated with biologics, and 136 (42%) received biologics as stand-alone (Fig. 3C) . CET, which was included in 32% of regimens, was the most commonly used targeted therapy in third line. Meanwhile, the share of PAN increased to 19% of third-line regimens, whereas that of BEV decreased to 18%.
Factors Associated With Biologics Receipt
Patients treated with a biologics-containing first-line regimen were 1. 
state buy-in assistance was less common in patients treated with biologics compared with those treated with chemotherapy alone (11% vs. 13%, p , .01) ( Table 3) . Table 3 shows that patients treated with biologics and patients treated with chemotherapy alone had similar makeup with regard to race, gender, marital status, and urban/rural living area. However, they differed with regard to certain comorbidities. Compared with those treated with chemotherapy alone, patients treated with biologics had lower CCI (p , .01) and were less likely to have a history of myocardial infarction (1% vs. 2%, p 5 .03), chronic heart failure (5% vs. 8%, p , .01), cerebrovascular disease (4% vs. 5%, p 5 .02), and chronic obstructive pulmonary disease (9% vs. 11%, p , .01). There were no statistically significant differences in prior chronic renal failure, peripheral vascular disease, or diabetes mellitus. Table 4 shows the results from our full logistic model, which estimated how the odds of biologics receipt changed across patient groups after adjusting for sociodemographic and clinical factors. We found that African Americans (odds ratio [OR] 0.77, p 5 .03), as well as patients with CCI of 1 (OR 0.83, p 5 .02) or .1 (OR 0.75, p , .01) were considerably less likely to receive biologics therapy. Furthermore, the odds of being treated with biologics decreased rapidly with age, resulting in a threefold difference between the youngest (66-69 age group) and the oldest ($75 age group) patients in our sample (OR 0.35, p , .01). Study participants with Medicare state buy-in had 2% lower odds of receiving biologics (OR 0.98, p 5 .04). Our sensitivity analyses produced qualitatively similar results.
DISCUSSION
After FDA approval, biologics use in the study sample increased sharply to 63% of first-line treatments and 73% of second-line treatments. After this initial uptake in use, rates of biologics receipt remained relatively steady for the remainder of the observation period. Bevacizumab was the most frequently prescribed biologic in both first-and second-line treatment. Cetuximab and panitumumab were used mostly in second-or later-line therapies, and cetuximab was the dominant biologic in third-line treatment.
The observed higher utilization of bevacizumab compared with cetuximab or panitumumab is consistent with the clinical strategy of providing first-line bevacizumab in patients with low risk for atherothrombotic complications; it is also consistent with the strategy of reserving EGFR inhibitors, which offer good response rates at the expense of greater toxicity, for second-or later-line treatment in all but exceptionally fit elderly patients [15] .
Our population-based findings are consistent with previous reports by Zafar et al. [18] and Hess et al. [19] , who used medical records data to answer questions about the use of biologics in metastatic colon cancer patients. Zafar The Oncologist ® metastatic colorectal cancer patients with median age of 62 and found that bevacizumab use was highest in first-line treatment, but as treatment progressed beyond first line, cetuximab use increased [19] .
Although the utilization of second-line biologics, as a group, remained steady, cetuximab receipt declined considerably in the second half of the observation period. At its peak in 2007, roughly one of three patients (28%) initiated second-line treatment with a cetuximab-containing regimen. In comparison, only one of five (19%) patients was given cetuximab in 2010. We believe that this decline was caused by increased KRAS testing.
Our multivariable results showed that older patients and patients with comorbidities were less likely to be treated with biologics. Low income also had a negative effect on the odds of receiving biologics. Finally, we observed significant disparities in access to biologic therapy across racial groups.
The strengths of the current study included using population-based claims data of elderly patients, who are often under-represented in clinical trials, and the use of a claims-based algorithm to identify lines of treatment, which allowed us to document how biologics use changed along the treatment continuum.
The primary limitation of our study was using older data (despite being the latest SEER-Medicare data available to researchers). A second limitation was the lack of KRAS and other test results, which are not reported on claims. A third limitation was that patients who started treatment with cetuximab (or panitumumab), and then stopped because of their KRAS test results, were still identified as cetuximab (or panitumumab) users.
Future research could assess the utilization patterns and rates of targeted therapies and genetic testing in commercial and more current datasets.
CONCLUSION
One of two elderly (age $66 years) SEER-Medicare patients in our study received targeted therapy as part of treatment for metastatic colon cancer disease. Initiation of biologics varied from year to year, fluctuating between 46% and 63% of firstline treatment regimens and 67% and 73% of second-line treatment regimens.
Bevacizumab accounted for virtually all biologics use in first line, and 68% in second line. One of three targeted therapy treatments in second line included cetuximab, which was the most frequently used biologic in third line (48% of biologics use). Panitumumab saw little use in second-line The Oncologist ® treatment, and it was used by 27% of targeted therapy patients in third line. Biologics were most commonly received with oxaliplatin in first-, irinotecan in second-, and by themselves in third-line treatment.Treatment progression from first to second line was primarily driven by the addition or change in chemotherapy drugs, whereas the progression to third-line treatment was primarily driven by discontinuation of chemotherapy.
After controlling for sociodemographic and clinical differences, we found that age, race/ethnicity, low income, and history of chronic heart failure had a statistically significant negative effect on the likelihood of receiving biologics among treated metastatic colon cancer patients. 
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